

Oncology Today with Dr Neil Love: Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Polatuzumab vedotin is currently approved for the treatment of recurrent diffuse large B-cell lymphoma (DLBCL) in combination with which agent or regimen?
 - a. Bendamustine/rituximab
 - b. Rituximab alone
 - c. Obinutuzumab
 - d. None of the above — polatuzumab vedotin is approved as monotherapy in this setting

2. Which of the following drug types best describes the mechanism of action of selinexor, which was recently approved for the treatment of relapsed/refractory (R/R) DLBCL?
 - a. Antibody-drug conjugate
 - b. Nuclear export protein XPO1 inhibitor
 - c. Anti-CD38 antibody

3. At which of the following targets on the surface of B cells is the novel agent tafasitamab directed?
 - a. PD-L1
 - b. CD20
 - c. CD19

4. Which of the following statements is FALSE regarding mosunetuzumab, which is under investigation for the treatment of DLBCL?
 - a. It is a bispecific antibody targeting CD3/CD20
 - b. It is not effective in patients with aggressive non-Hodgkin lymphoma who have received prior CAR (chimeric antigen receptor) T-cell therapy
 - c. It has been associated with cytokine release syndrome